Drug intelligence / Profile preview

Inogest

Development stage: Unknown
Lead developer: Meditrina Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Inogest is a medical food and dietary supplement developed by MEDITRINA for the dietary management of polycystic ovary syndrome (PCOS). It is a combination product containing myo-inositol, N-acetyl-cysteine (NAC), folic acid, and Nutriose fiber. Myo-inositol acts as an insulin sensitizer, playing a crucial role in the insulin signaling pathway to improve metabolic and reproductive outcomes in women with PCOS. N-acetyl-cysteine provides antioxidant support and may further enhance insulin sensitivity by modulating oxidative stress. Folic acid is included for its role in DNA synthesis and fetal development, while Nutriose fiber aids in metabolic regulation. The product is administered orally as a powder dissolved in water.

Brand names: Inogest

Targets

INSR (Insulin receptor)FOLR1 (FRα)

Beyond the preview

Go deeper on Inogest.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inogest.

Explore the full profile